Alvogen To Buy Dream For $187M In APAC Expansion
This article was originally published in PharmAsia News
Executive Summary
South Korea's Dream Pharma has agreed to be acquired by Alvogen for $187 million in cash as the U.S.-based generics maker expands its holdings in the Asia-Pacific region.